期刊文献+

膀胱尿路上皮癌中MHC Ⅰ类链相关蛋白A的表达及临床意义 被引量:1

Expression and Clinical Significance of Major Histocompatibility Complex Class Ⅰ Chain-relatived A Protein in Urothelial Carcinoma of Urinary Bladder
下载PDF
导出
摘要 目的:探讨膀胱尿路上皮癌中MHCI类链相关蛋白A(MICA)的表达及临床意义。方法:用免疫组化检测75例膀胱尿路上皮癌及15例正常膀胱黏膜中MICA蛋白表达,对MICA蛋自在膀胱黏膜、不同级别及分期的膀胱癌中的表达进行统计学分析。结果:MICA蛋白在膀胱癌的表达率(48.0%)高于正常膀胱黏膜(P〈0.05),其中在非浸润性尿路上皮癌的表达率为59.0%(P〈0.05),浸润性36.1%;高、低级别非浸润性癌MICA蛋白表达无统计学意义;MICA蛋白在Ta、T1和T2-4期膀胱癌的表达率分别为59.0%、41.2%和31.6%,MICA蛋白在浸润性膀胱癌(T1-4)的表达低于非浸润性膀胱癌(Ta)(P〈0.05)。结论:MICA蛋白表达上调可能与膀胱尿路上皮癌的发生有关。而MICA蛋白表达缺失可能与膀胱癌的浸润有关。MICA蛋白可作为膀胱癌免疫治疗的候选治疗靶点。 Objective: To investigate the expression and clinical significance of major histocompatibility complex class I chain-relatived A protein(MICA)in urothelial carcinoma of urinary bladder. Methods: MICA expression in 75 urothelial carcinoma tissues and 15 normal mucous membrane tissues of the bladder was detected by immunohistochemistry. The differences between MICA expression in mucous membrane tissues, different grade and stage carcinoma were analyzed by statistics. Results: The expression rates of MICA protein in urothelial carcinoma, noninvasive and invasive umthelial carcinoma were 48.0%, 59.0% and 36.1%, respectively. Up-regulation of MICA expression was found in urothelial carcinoma compared with normal mucous membrane tissues( P 〈 0.05). There was no significant difference of MICA expression between low grade noninvasive carcinoma and high grade invasive carcinoma. The MICA expression rates of Ta, T1 and T2-4 stage carcinoma were 59.0%, 41.2% and 31.6%, respectively. Lower MICA expression was detected in in- vasive carcinoma( P 〈 0.05). Conclusion: Up-regulation of MICA expression may correlate with the tumorigenesis of urinary bladder. Loss of MICA protein may play a role in tumor invasion. MICA protein may be regarded as a putative target for immunothempy on carcinoma of urinary bladder.
出处 《汕头大学医学院学报》 2010年第1期29-31,F0004,共4页 Journal of Shantou University Medical College
基金 汕头市重点科技计划项目
关键词 膀胱癌 MI-IC I类链相关蛋白A 表达 carcinoma of urinary bladder, major histocompatibility complex class I chain-related A, expression
  • 相关文献

参考文献10

  • 1蒋翡翎,单保恩.卡介苗治疗膀胱癌的免疫机制与研究进展[J].中国热带医学,2005,5(3):640-642. 被引量:3
  • 2RAULET D H. Roles of the NKG2D immunoreceptor and its ligands[J]. Nat Rev Immuno, 2003, 3(10): 781 -790.
  • 3WATSON N F, SPENDLOVE I, MADJD Z, et al. Expression of the stress-related MHC class Ⅰ chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients[J]. Int J Cancer, 2006, 118(6) : 1445 - 1452.
  • 4MADJD Z, SPENDLOVE I, MOSS R, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma[J]. Cancer Immun, 2007, 7: 17.
  • 5JINUSHI M, TAKEHARA T, TATSUMI T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid[J]. Int J Cancer, 2003, 104(3) : 354- 361.
  • 6LU S M, XIAO P, XUE L, et al. Prevalent expression of MHC class Ⅰ chain-related molecule A in human osteosarcoma [J]. Neoplasma, 2008, 55(3): 266-272.
  • 7肖萍,薛玲,车丽洪,吴惠茜,乔慧.膜型/可溶型MHCⅠ类链相关分子A及其受体NKG2D在骨肉瘤中的表达及其意义[J].中华病理学杂志,2007,36(9):596-599. 被引量:4
  • 8WU J D, HIGGINS L M, STEINLE A, et al. Prevalent expression of the immunostimulatory MHC class Ⅰ chain-related molecule is counteracted by shedding in prostate cancer[J]. J Chin Invest, 2004, 114(4) : 560- 568.
  • 9GROH V, WU J, YEE C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation[J]. Nature, 2002, 419(6908): 734-738.
  • 10SALIH H R, RAMMENSEE H G, STEINLE A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding[J]. J Immunol, 2002, 169(8): 4098- 4102.

二级参考文献31

  • 1Suttmann H,Jacobsen M,Reissk,et al.Mechanisms of bacillus calmette-Guérin mediated natural killer cell activation[J].Jurol,2004,172:1490~1495.
  • 2Akaza H,Koiso K,Ozono S,et al.A clinical Study of PMCJ-9(Bacillus Calmette-Guérin connaught strain).Treatment of superficial Bladder cancer and carcinoma situ of the Bladder[J].Jpn J Clin Oncol,2003,33(8):382~390.
  • 3Morales A.Chin JL,Ramsey EWJ,et al.Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder[J].Urol,2001,166(5):1633~1637.
  • 4Hu J,chen H,zhou L,et al.The effect of BCG-PSN on T-cell subsets and cytokines in vernal conjunctivitis[J].J Huazhong University Technolog Med Sci,2002,22(1):77~79.
  • 5Tokunaga T,Yamamoto H,shimada S,et al.Antitumov activity of deoxyribonucleic acid fraction from Mycobacteriun bovis BCG.Isolation physicochemical characterization,and antitumor activity[J].Journal of the National Cancer Institute,1984,72:955~962.
  • 6Hartmann G,Weiner GJ,Krieg AM,et al.CPG DNA: a potent signal for growth,activation,and maturation of human dendritic cells[J].PNAs,1999,96:9305~9310.
  • 7Heckels MK,Rall K,Beck S,et al.Peritumoral CpG DNA elicits a coordinated response of CD8T cells and innate offectors to cure established tumors in a murine colon carcinoma model[J].Journal of immunology,2002,169(7):3892~3899.
  • 8Dhar N,Rao V,Tyagi AK,et al.Skewing of the Th1/Th2 responses in the level of expression of an antigen in a recombinant BCG system[J].Immunol lettt,2003,88(3):175~184.
  • 9Arnold J,de Boer EC,O'Donnell IIIA,et al.Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma[J].J Immunother,2004,27(2):116~123.
  • 10Yamada H,Matsumoto S,Matsumoto T,et al.Murine IL-2 Secreting recombinant Bacillus calmette-Guérin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2[J].Jurol,2000,164(2):526~531.

共引文献5

同被引文献15

  • 1Higuchi T, Shimizu M, Owaki A, et al. A possible mechanism of intravesical BCG therapy for human blad- der carcinoma: involvement of innate effector cells for the inhibition of tumor growth[J]. Cancer Immunol Immunother, 2009, 58(8) : 1245-1255.
  • 2Duenas-Gonzalez A, Candelaria M, Perez-Plaseencia C, et al. Valproic acid as epigenetic cancer drug: pre- clinical, clinical and transcriptional effects on solid tumors[J]. Cancer Treat Rev, 2008, 34(3): 206- 222.
  • 3Nausch N, Cerwenka A. NKG2D ligands in tumor im- munity[J]. Oncogene, 2008, 27(45): 5944-5958.
  • 4Barber A, Zhang T, DeMars L R. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer[J]. Cancer Res, 2007, 67(10): 5003-5008.
  • 5Busche A, Goldmann T, Naumann U, et al. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histo- compatibility complex class I chain-related gene A[J]. Hum Gene Ther, 2006, 17(2): 135-146.
  • 6Carafa V, Miceli M, Altucci L, et al. Histone deacety- lase inhibitors: a patent review (2009 - 2011)[J]. Expert Opin Ther Pat, 2013, 23(1): 1-17.
  • 7Khan A N, Tomasi T B. Histone deaeetylase regula- tion of immune gene expression in tumor cells[J]. Im- munol Res, 2008, 40(2) : 164-78.
  • 8Byun S S, Kim F J, Khandrika L, et al. Differential effects of valproic acid on growth, proliferation and me- tastasis in HTB5 and HTB9 bladder cancer cell lines [J]. Cancer Lett, 2009, 281(2): 196-202.
  • 9Chen C L, Sung J, Cohen M, et al. Valproic acid in- hibits invasiveness in bladder cancer but not in prostate cancer cells[J]. J Pharmacol Exp Ther, 2006, 319(2) 533-542.
  • 10Armeanu S, Bitzer M, Lauer U M. Natural killer cell- mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor so- dium valproate[J]. Cancer Research, 2005, 65 (14): 6321-6329.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部